ATE462437T1 - Krebstherapie mit ganzen glukan-teilchen und antikörpern - Google Patents

Krebstherapie mit ganzen glukan-teilchen und antikörpern

Info

Publication number
ATE462437T1
ATE462437T1 AT03749452T AT03749452T ATE462437T1 AT E462437 T1 ATE462437 T1 AT E462437T1 AT 03749452 T AT03749452 T AT 03749452T AT 03749452 T AT03749452 T AT 03749452T AT E462437 T1 ATE462437 T1 AT E462437T1
Authority
AT
Austria
Prior art keywords
glucan particles
whole glucan
antibodies
cancer therapy
immune system
Prior art date
Application number
AT03749452T
Other languages
German (de)
English (en)
Inventor
Gary Ostroff
Gordon Ross
Original Assignee
Biopolymer Engineering Inc
Univ Louisville Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE462437(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biopolymer Engineering Inc, Univ Louisville Res Found filed Critical Biopolymer Engineering Inc
Application granted granted Critical
Publication of ATE462437T1 publication Critical patent/ATE462437T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT03749452T 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern ATE462437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40812602P 2002-09-04 2002-09-04
PCT/US2003/027841 WO2004021994A2 (en) 2002-09-04 2003-09-04 Cancer therapy using whole glucan particles and antibodies

Publications (1)

Publication Number Publication Date
ATE462437T1 true ATE462437T1 (de) 2010-04-15

Family

ID=31978563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03749452T ATE462437T1 (de) 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern

Country Status (9)

Country Link
US (3) US8883760B2 (https=)
EP (3) EP2181711A1 (https=)
JP (1) JP2006502167A (https=)
CN (3) CN1939335A (https=)
AT (1) ATE462437T1 (https=)
AU (2) AU2003295326A1 (https=)
CA (2) CA2496508C (https=)
DE (1) DE60331925D1 (https=)
WO (2) WO2004021994A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US8883760B2 (en) * 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP2070546A1 (en) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
WO2007146440A2 (en) 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
EP2062588A4 (en) * 2006-08-24 2011-06-08 Kirin Holdings Kk COMPOSITION FOR TREATING A SKIN CONDITION
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
WO2009103115A1 (en) * 2008-02-19 2009-08-27 Novogen Research Pty Ltd Evaluating the therapeutic potential of a glucan
US20110053855A1 (en) * 2008-02-19 2011-03-03 Novogen Research Pty Ltd. Ex vivo cell stimulation
WO2013040027A1 (en) * 2011-09-12 2013-03-21 Baylor Research Institute Reprogramming immune environment in breast cancer via dendritic cells
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
BR112014027989A2 (pt) 2012-05-07 2017-07-18 Algal Scient Corporation processo multi-etapas para produção de modulador imunológico
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP6372890B2 (ja) * 2013-03-08 2018-08-15 学校法人東京理科大学 乳酸菌増殖促進剤、制御性ｔ細胞増加剤、乳酸菌増殖促進方法、制御性ｔ細胞を増加させる方法、制御性ｔ細胞増加効果の評価方法、および乳酸菌増殖促進効果の評価方法
EP2832360A1 (en) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse
MX2016007148A (es) * 2013-12-05 2016-12-07 Biothera Inc Metodos de ensayo de beta-glucano.
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
EP3215163B1 (en) 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
US20180110853A1 (en) * 2016-10-21 2018-04-26 Wisconsin Alumni Research Foundation Vaccine Adjuvant
WO2018106645A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
WO2018106644A1 (en) * 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CN110582209A (zh) 2017-04-10 2019-12-17 基博生物技术公司 用于消化系统健康，控制体重，增强免疫力和改善健康的多纤维益生元组合物
MX2020009510A (es) 2018-03-13 2021-08-05 Hibercell Inc Inmunoterapia combinada de beta glucano y agonista cd40.
WO2021049587A1 (ja) * 2019-09-11 2021-03-18 株式会社アウレオ 抗体医薬の効果増強用組成物
EP3858362A1 (en) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission
EP4096685A1 (en) * 2020-01-29 2022-12-07 Pleuran, s.r.o. Beta-glucan for use in modulation of an immune response in a remission
WO2022251123A1 (en) * 2021-05-24 2022-12-01 Frank Jordan Alkaline extraction of beta glucan compounds for use in anti-viral and immune therapies
US12433915B2 (en) 2022-11-23 2025-10-07 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
JPS58220989A (ja) * 1982-06-14 1983-12-22 Diesel Kiki Co Ltd 可変容量式ベ−ン型圧縮機
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5082936A (en) * 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5037972A (en) * 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
KR0141685B1 (ko) * 1988-09-01 1998-07-01 야마따니 와따루 참게 아메보사이트 라이세이트 g 인자 활성화 저해제
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
IT1232310B (it) 1989-09-04 1992-01-28 Consiglio Nazionale Ricerche Processo per la preparazione di un prodotto contenente glucano a partire da candida albicans bmm-12
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0491829B1 (en) 1989-09-08 1997-06-04 Alpha Beta Technology, Inc. Composition for immune system activation
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JP2911554B2 (ja) * 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3122454B2 (ja) * 1990-09-27 2001-01-09 生化学工業株式会社 カブトガニ・アメボサイト・ライセートの調製法
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IT1256035B (it) 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche Glucani ad attivita' immunostimolante
US5453124A (en) * 1992-12-30 1995-09-26 Texas Instruments Incorporated Programmable multizone gas injector for single-wafer semiconductor processing equipment
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
GB9420645D0 (en) * 1994-10-13 1994-11-30 Dow Chemical Co Non-linear stytrenic polymer compositions and articles prepared therefrom
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6036946A (en) * 1997-12-24 2000-03-14 Shaklee Corporation Methods for protecting skin from damaging effects of ultraviolet light
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
EP1357919B1 (en) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US8883760B2 (en) 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
CN1964722A (zh) 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒

Also Published As

Publication number Publication date
WO2004030613A2 (en) 2004-04-15
US20150064199A1 (en) 2015-03-05
CN1694715B (zh) 2010-12-01
CA2496508A1 (en) 2004-04-15
WO2004030613A3 (en) 2005-01-13
EP1536820A2 (en) 2005-06-08
WO2004021994A2 (en) 2004-03-18
CA2496508C (en) 2014-04-22
AU2003295326A1 (en) 2004-04-23
CA2496596A1 (en) 2004-03-18
EP1539194A4 (en) 2007-06-13
US8883760B2 (en) 2014-11-11
AU2003268486A1 (en) 2004-03-29
CN100363054C (zh) 2008-01-23
DE60331925D1 (de) 2010-05-12
JP2006502167A (ja) 2006-01-19
US20060009419A1 (en) 2006-01-12
CN1939335A (zh) 2007-04-04
US9522187B2 (en) 2016-12-20
EP1536820B1 (en) 2010-03-31
WO2004021994A3 (en) 2004-08-12
EP1536820A4 (en) 2007-06-20
CA2496596C (en) 2016-06-28
CN1694715A (zh) 2005-11-09
CN1697659A (zh) 2005-11-16
US20170056432A1 (en) 2017-03-02
EP1539194A2 (en) 2005-06-15
EP2181711A1 (en) 2010-05-05
EP1536820B2 (en) 2013-10-23
AU2003295326A8 (en) 2004-04-23
AU2003268486A8 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
DE60331925D1 (de) Krebstherapie mit ganzen glukan-teilchen und antikörpern
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
UA109108C2 (uk) Антитіло до pd-l1 та його застосування для посилення функції t-клітин
PL2135881T3 (pl) Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
GEAP202014811A (en) Ctla4 binders
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
NO20016007D0 (no) Rekombinant anti-CD40-antistoff og anvendelser derav
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO2011070214A3 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
WO2004071404A3 (en) Use of il-6 antagonists in combination with steroids to enhance apoptosis
EP3674321A3 (en) Anti-met antibodies and uses thereof
MX2021002605A (es) Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
TW200801038A (en) Immunoglobulins
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
WO2007144046A3 (de) Mittel zur behandlung von malignen erkrankungen
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2006085895A3 (en) Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties